Jeff Jones
Stock Analyst at Oppenheimer
(0.79)
# 3,755
Out of 4,874 analysts
93
Total ratings
21.43%
Success rate
-19.34%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $22.42 | +96.25% | 3 | Jun 24, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $20 → $15 | $4.80 | +212.50% | 3 | May 29, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $11 → $10 | $1.21 | +726.45% | 8 | May 16, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $3.03 | +725.08% | 2 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $1.16 | +1,371.86% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $4.02 | +323.25% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $32.02 | +168.58% | 2 | May 8, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $60 → $56 | $8.11 | +590.51% | 9 | May 7, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $10.80 | +66.67% | 4 | Jan 24, 2025 | |
| CLRB Cellectar Biosciences | Downgrades: Perform | n/a | $7.88 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $3.69 | +333.60% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $2.47 | +265.11% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $56 | $44.77 | +25.08% | 4 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.38 | +3,160.87% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.32 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.10 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,920 | $0.36 | +537,027.54% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.21 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.13 | +1,227.43% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.39 | +19,160.40% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $2.68 | +40,944.78% | 2 | Nov 17, 2022 |
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $22.42
Upside: +96.25%
Y-mAbs Therapeutics
May 29, 2025
Maintains: Outperform
Price Target: $20 → $15
Current: $4.80
Upside: +212.50%
Chemomab Therapeutics
May 16, 2025
Maintains: Outperform
Price Target: $11 → $10
Current: $1.21
Upside: +726.45%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $3.03
Upside: +725.08%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $1.16
Upside: +1,371.86%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $4.02
Upside: +323.25%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $32.02
Upside: +168.58%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Outperform
Price Target: $60 → $56
Current: $8.11
Upside: +590.51%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $10.80
Upside: +66.67%
Cellectar Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $7.88
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.69
Upside: +333.60%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $2.47
Upside: +265.11%
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $44.77
Upside: +25.08%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.38
Upside: +3,160.87%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $9.32
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.10
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $1,920
Current: $0.36
Upside: +537,027.54%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $3.21
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.13
Upside: +1,227.43%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.39
Upside: +19,160.40%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $2.68
Upside: +40,944.78%